Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xin Sheng Hua Granules is a Traditional Chinese Medicine (TCM) product developed and manufactured by Beijing Yadong Biopharmaceutical (also known as Beijing ASIA-EAST Biopharmaceutical). It is primarily used in gynecology for postpartum recovery. The formula is a modification of the classic Shenghua Tang, typically containing ingredients such as Angelica sinensis, Ligusticum chuanxiong, and Leonurus japonicus. It functions by promoting blood circulation to resolve blood stasis and nourishing new blood. Clinically, it is indicated for the treatment of postpartum lochia retention, abdominal pain caused by blood stasis, and to assist in uterine involution. The preparation is an approved pharmaceutical product in China, widely utilized in obstetric clinical practice to ensure the complete discharge of postpartum debris and support uterine health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xin sheng hua granules.